Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria

J van Ingen, MJ Boeree, D van Soolingen… - Drug Resistance …, 2012 - Elsevier
Nontuberculous mycobacteria (NTM) are increasingly recognized as causative agents of
opportunistic infections in humans. For most NTM infections the therapy of choice is drug …

Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?

O Alfarisi, WA Alghamdi, MH Al-Shaer… - Expert review of …, 2017 - Taylor & Francis
Introduction: One-third of the world's population is infected with Mycobacterium tuberculosis
(M. tb.). Latent tuberculosis infection (LTBI) can progress to tuberculosis disease, the leading …

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 …

RO Phillips, J Robert, KM Abass, W Thompson… - The Lancet, 2020 - thelancet.com
Background Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans
infection that damages the skin and subcutis. It is most prevalent in western and central …

The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium avium Complex Disease Treatment

J van Ingen, EF Egelund, A Levin… - American journal of …, 2012 - atsjournals.org
Rationale: Currently recommended multidrug treatment regimens for Mycobacterium avium
complex (MAC) lung disease yield limited cure rates. This results, in part, from incomplete …

Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC–MS/MS

DH Vu, RA Koster, MS Bolhuis, B Greijdanus… - Talanta, 2014 - Elsevier
Introduction Rifampicin (RIF) and clarithromycin (CLR) are common drugs for the treatment
of infections like Mycobacterium tuberculosis and Mycobacterium ulcerans. Treatment for …

Infections caused by non-tuberculous mycobacteria in recipients of hematopoietic stem cell transplantation

KA Al-Anazi, AM Al-Jasser, WK Al-Anazi - Frontiers in oncology, 2014 - frontiersin.org
Non-tuberculous mycobacteria (NTM) are acid-fast bacteria that are ubiquitous in the
environment and can colonize soil, dust particles, water sources, and food supplies. They …

Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams

MS Bolhuis, PN Panday, AD Pranger, JGW Kosterink… - Pharmaceutics, 2011 - mdpi.com
Like any other drug, antimicrobial drugs are prone to pharmacokinetic drug interactions.
These drug interactions are a major concern in clinical practice as they may have an effect …

Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)

RR Yotsu, M Richardson, N Ishii - Cochrane Database of …, 2018 - cochranelibrary.com
Background Buruli ulcer is a necrotizing cutaneous infection caused by infection with
Mycobacterium ulcerans bacteria that occurs mainly in tropical and subtropical regions. The …

Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of …

RO Phillips, FS Sarfo, MK Abass, J Abotsi… - Antimicrobial agents …, 2014 - journals.asm.org
Buruli ulcer, an ulcerating skin disease caused by Mycobacterium ulcerans infection, is
common in tropical areas of western Africa. We determined the clinical and microbiological …

Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review

L Verrest, TPC Dorlo - Clinical pharmacokinetics, 2017 - Springer
Abstract Introduction Neglected tropical diseases (NTDs) affect more than one billion
people, mainly living in develo** countries. For most of these NTDs, treatment is …